Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model

Statistics in Medicine

Volumn 32, Issue 2, 2013, Pages 240-254

  Fu, Haoda ^a   Wang, Yanping ^a   Liu, Jingyi ^a   Kulkarni, Pandurang M ^a   Melemed, Allen S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bayesian method; Cancer clinical trials; Gaussian copula; Joint modeling; Overall survival; Progression free survival; Semi competing risks; Time to progression

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PEMETREXED;

ARTICLE; BAYES THEOREM; CANCER SURVIVAL; DECISION MAKING; DISEASE COURSE; HAZARD RATIO; LUNG SMALL CELL CANCER; NORMAL DISTRIBUTION; NORMAL INDUCED COPULA ESTIMATION MODEL; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL TIME;

BAYES THEOREM; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; MODELS, STATISTICAL; NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84871291846     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5487     Document Type: Article

References (46)

1. Stone AM, Bushnell W, Denne J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, Helterbrand J, Williams G. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. European Journal of Cancer 2011; 47(12):1763-1771.
2. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. The New England Journal of Medicine 2007; 357(26):2666-2676.
3. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck, N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology 2010; 28(20):3239-3247.
4. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan, S C, O'Shaughnessy J. Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. Journal of Clinical Oncology 2011; 29(10):1252-1260.
5. Axelrod RC. The significance of progression-free survival as a clinical end point in oncology. Drug Benefit Trends 2010; 22(2):39-45.
6. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. Journal of Clinical Oncology 2007; 25(29):4562-4568.
7. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P. Progression-free survival is a surrogate for survival in advanced colorectal cancer. Journal of Clinical Oncology 2007; 25(33):5218-5224.
8. Goldman B, LeBlanc M, Crowley J. Interim futility analysis with intermediate endpoints. Clinical Trials 2008; 5(1):14-22.
9. Kendall MG.A new measure of rank correlation. Biometrika 1938; 30(1):81-89.
10. Spearman C. The proof and measurement of association between two things. American Journal of Psychology 1904; 15:72-101.
11. Wang WJ, Wells MT. Estimation of Kendall's tau under censoring. Statistica Sinica 2000; 10(4):1199-1215.
12. Lim J. Permutation procedures with censored data. Computational Statistics & Data Analysis 2006; 50(2):332-345.
13. Beaudoin D, Duchesne T, Genest C. Improving the estimation of Kendall's tau when censoring affects only one of the variables. Computational Statistics & Data Analysis 2007; 51(12):5743-5764.
14. FDA. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Biotechnology Law Report 2007; 26(4):375-386.
15. WHO. Who Handbook for Reporting Results of Cancer Treatment, WHO offset publication. World Health Organization: Geneva, 1979.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000; 92(3):205-216.
17. Link WA.A model for informative censoring. Journal of the American Statistical Association 1989; 84(407):749-752.
18. Emoto SE, Matthews PC.A Weibull model for dependent censoring. Annals of Statistics 1990; 18(4):1556-1577.
19. Peterson AV. Bounds for a joint distribution with subdistribution functions: application to competing risks. Proceedings of the National Academy of Sciences of the United States of America 1976; 73:11-13.
20. Slud EV, Rubinstein LV. Dependent competing risks and summary survival curves. Biometrika 1983; 70:643-649.
21. Klein JP, Moeschberger ML. Bounds on net survival probabilities for dependent competing risks. Biometrics 1988; 44(2):529-538.
22. Scharfstein DO, Robins JM. Estimation of the failure time distribution in the presence of informative censoring. Biometrika 2002; 89(3):617-634.
23. Aalen OO, Johansen S. An empirical transition matrix for nonhomogeneous markov chains based on censored observations. Scandinavian Journal of Statistics 1978; 5:141-150.
24. Andersen PK. Statistical Models Based on Counting Processes, Springer series in statistics. Springer-Verlag: New York, 1993.
25. Dejardin D, Lesaffre E, Verbeke G. Joint modeling of progression-free survival and death in advanced cancer clinical trials. Statistics in Medicine 2010; 29(16):1724-1734.
26. Fine JP, Jiang H, Chappell R. On semi-competing risks data. Biometrika 2001; 88(4):907-919.
27. Wang WJ. Estimating the association parameter for copula models under dependent censoring. Journal of the Royal Statistical Society Series B-Statistical Methodology 2003; 65:257-273.
28. Peng L, Fine JP. Regression modeling of semicompeting risks data. Biometrics 2007; 63(1):96-108.
29. Peng L, Jiang H, Chappell RJ, Fine JP. An overview of the semi-competing risks problem Chapter 11 in Statistical Advances in the Biomedical Sciences: Clinical Trials, Epidemiology, Survival Analysis, and Bioinfomatics. Wiley: Hoboken, New Jersey, 2008.
30. Carlin BP, Louis TA. Bayesian Methods for Data Analysis, 3rd ed., Chapman & Hall/CRC texts in statistical science series. CRC Press: Boca Raton, 2009.
31. Berry SM, Carlin BP, Lee J, Muller P. Bayesian Adaptive Methods for Clinical Trials, Chapman & Hall/CRC biostatistics series. Chapman & Hall/CRC: Boca Raton, 2010.
32. Li Y, Prentice RL, Lin XH. Semiparametric maximum likelihood estimation in normal transformation models for bivariate survival data. Biometrika 2008; 95(4):947-960.
33. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, 2nd ed., Wiley series in probability and statistics. John Wiley & Sons, Ltd: Hoboken, New Jersey, 2002.
34. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data, 2nd ed., Statistics for biology and health. Springer: New York, 2003.
35. Gelman A. Bayesian Data Analysis, 2nd ed., Texts in statistical science. Chapman & Hall/CRC: Boca Raton, Florida, 2004.
36. Shao J. Mathematical Statistics, 2nd ed., Springer texts in statistics. Springer: New York, 2003.
37. Sklar A. Distribution functions of n dimensions and margins. Public Institute Statistical University, Paris 1959; 8:229-231.
38. Plackett RL.A class of bivariate distributions. Journal of the American Statistical Association 1965; 60:516-522.
39. Clayton DG.A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 1978; 65:141-151.
40. Genest C, Mackay J. The joy of copulas: bi-variate distributions with uniform marginals. American Statistician 1986; 40:280-283.
41. Shih JH, Louis TA. Inferences on the association parameter in copula models for bivariate survival data. Biometrics 1995; 51(4):1384-1399.
42. Genest C, Ghoudi K, Rivest LP.A semiparametric estimation procedure of dependence parameters in multivariate families of distributions. Biometrika 1995; 82(3):543-552.
43. Flandre P, O'Quigley J.A two-stage procedure for survival studies with surrogate endpoints. Biometrics 1995; 51(3):969-976.
44. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. Journal of Clinical Oncology 2009; 27(28):4787-4792.
45. O'Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4(3):187-201.
46. Chuang-Stein C. Sample size and the probability of a successful trial. Pharmaceutical Statistics 2006; 5(4):305-309.